Use of metyrosine in the anaesthetic management of patients with catecholamine-secreting tumours. A case report.
Metyrosine 1.5 g daily for days decreased 24-h urine metanephrine concentration by about 60% in a patient with multiple catecholamine-secreting paragangliomas. Despite the considerable inhibition of catecholamine synthesis, this patient exhibited stress-induced sympathetic overactivity, indicated by increases in arterial pressure and serum catecholamine and urine metanephrine concentrations. It is concluded that metyrosine should be introduced early to the preoperative regimen. In this way, optimal inhibitory effect on catecholamine synthesis can be obtained and maintained for a sufficient time to allow catecholamine stores to become as close to normal as possible. Attainment of the optimal therapeutic effect is not clearly defined, but would seem to be best gauged by a combination of clinical tests of sympathetic responses and of suppression of urinary excretion of metanephrines or VMA.
D000767:Anesthesia, Epidural; D002395:Catecholamines / Q000378:metabolism*; D006552:Hernia, Inguinal / Q000601:surgery; D006801:Humans; D007432:Intraoperative Period; D008297:Male; D008781:Methyltyrosines / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010235:Paraganglioma / Q000378:metabolism*; D011292:Premedication; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors; D019805:alpha-Methyltyrosine
D002395:Catecholamines; D008781:Methyltyrosines; D019805:alpha-Methyltyrosine; D014446:Tyrosine 3-Monooxygenase